Abstract
Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are well modulated by Jade-1, which mainly regulates cell proliferation and apoptosis. Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic renal diseases. This review aims to provide a basis of disease prevention or therapy.
Keywords: Jade-1, pVHL, renal cancer, renal cyst, HAT, β-catenin.
Current Molecular Medicine
Title:Jade-1: its structure, regulation and functions in the renal cancer.
Volume: 16 Issue: 1
Author(s): Y.-C. Zhang, W.-Q. Du, R.-Y. Zhang, J.-N. Zheng and D.-S. Pei
Affiliation:
Keywords: Jade-1, pVHL, renal cancer, renal cyst, HAT, β-catenin.
Abstract: Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are well modulated by Jade-1, which mainly regulates cell proliferation and apoptosis. Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic renal diseases. This review aims to provide a basis of disease prevention or therapy.
Export Options
About this article
Cite this article as:
Zhang Y.-C., Du W.-Q., Zhang R.-Y., Zheng J.-N. and Pei D.-S., Jade-1: its structure, regulation and functions in the renal cancer., Current Molecular Medicine 2016; 16(1) . https://dx.doi.org/10.2174/1566524016666151222144511
DOI https://dx.doi.org/10.2174/1566524016666151222144511 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Targeted-Therapy in Advanced Renal Cell Carcinoma
Current Medicinal Chemistry Radiometal Complexes in Molecular Imaging and Therapy
Current Medicinal Chemistry Quality Control of Traditional Chinese Medicine by Monoclonal Antibody Method
Current Drug Discovery Technologies Editorial
Current Radiopharmaceuticals New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology p38 MAPK: A Potential Target of Chronic Pain
Current Medicinal Chemistry Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Ultrasound Contrast Imaging in Cancer –Technical Aspects and Prospects
Current Molecular Imaging (Discontinued) Dinuclear Berenil-Platinum (II) Complexes as Modulators of Apoptosis in Human MCF-7 and MDA-MB231 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology